Latest news

• Roche trumpets APHINITY data, but did it hit the mark?

  The results of the APHINITY trial could present an opportunity to US biotech Puma, which won a positive recommendation from an FDA advisory committee for its neratinib candidate in post-surgery ... In trials, neratinib achieved a 33% reduction in the

• FDA panel backs Puma's breast cancer drug, with reservations

  US biotech Puma took a step closer to approval of its breast cancer therapy neratinib after an FDA advisory committee voted in favour of the drug. ... A number of analysts have suggested neratinib may be approved only in patients with hormone

• Oncology bias in pharma deals

  Pfizer has licensed the worldwide commercial rights of Neratinib, a phase II pan-HER inhibitor (potent irreversible tyrosine kinase inhibitor) in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive ... 2 ##. Pfizer/Puma Biotechnology ##

• Never-ending story: modernising clinical trial design

  I-SPY 2 has already brought together compounds from Pfizer (neratinib), Abbott Laboratories (ABT-888) and Takeda Pharmaceutical Industries (AMT-386), and there appears to be an almost unprecedented level of

• Multi-pronged approach

  HER2 inhibitor neratinib (Pfizer) and the PARP inhibitor veliparib (Abbott Laboratories).